Marked Chart Marked Chart Closed

The Marked Chart Wire · Series of events

Series of events · AstraZeneca Acquisition

AstraZeneca moves on drugs and acquisition

AstraZeneca advanced a cancer drug filing, reported strong quarterly results, and reportedly bid for a rival.

3 eventsOct 25 to Nov 4AZN+2.8%GILD+4.2%NVS+3.6%TAK+1.5%RYTM+28.0%

Updated

The flow in 3 points

  1. Sonesitatug vedotin filing follows 42 percent death risk reduction
  2. Q3 profit reached $3.12 billion, up from $2.53 billion
  3. Reportedly bid $10 billion for Rhythm Pharmaceuticals

What happened, in order

Times are Eastern

  1. Where it began

    Cancer drug filing

    AstraZeneca plans to file for sonesitatug vedotin approval after a trial showed a 42 percent reduction in death risk.

    Read the story

  2. Q3 profit rise

    AstraZeneca reported Q3 profit of $3.12 billion and reiterated its full-year 2026 revenue and core EPS targets.

    Read the story

  3. Latest

    Acquisition bid

    AstraZeneca is said to have submitted a $10 billion acquisition proposal for Rhythm Pharmaceuticals.

    Read the story

How they connect

The company first detailed a new drug filing plan, then reported quarterly financial results, and finally reportedly made a large acquisition offer.

The stocks in this series

  1. AZN+2.8%AstraZeneca$189.01
  2. GILD+4.2%Gilead Sciences$174.48
  3. NVS+3.6%Novartis$164.98
  4. TAK+1.5%Takeda$21.06
  5. RYTM+28.0%Rhythm$110.68

Prices from Based on Wed, Nov 4 close · Opens Thu 9:30 AM ET. Each tile opens the stock's chart and news.

All series of events

A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.